Field Notes · July 4, 2026 · 6 min · By Kira Vandenberg
What your skin biopsy report means before Mohs surgery
The pathology report is the document that decides the plan; here is how to read it.
The biopsy report is the document that determines whether Mohs surgery is recommended at all, and its two most important lines are the diagnosis and the subtype. Everything else on the page, the site, the margins, the microscopic description, adds detail to those two facts. Learning to read them takes minutes and turns the surgical consult from a lecture into a conversation.
Start with the diagnosis line. Most reports that lead to Mohs name one of two cancers: basal cell carcinoma or squamous cell carcinoma, the two most common skin cancers and the ones the technique treats most often. The differences between them, in behavior and urgency, are covered in basal cell vs. squamous cell carcinoma. If the report instead reads actinic keratosis, that is a precancer, not a cancer, and is usually treated far more simply. Melanoma is a different disease with its own staging and its own surgical playbook, and it follows a separate path from the one described here.
The subtype tells the surgeon how the tumor grows. For basal cell carcinoma, words like nodular and superficial describe contained, well-behaved growth patterns, while infiltrative, morpheaform, sclerosing, and micronodular describe tumors that send thin strands beyond what the eye can see. For squamous cell carcinoma, well differentiated means the cells still resemble normal skin and generally behave less aggressively, while poorly differentiated signals the opposite. Aggressive subtypes are precisely where the margin-by-margin checking described in what is Mohs surgery earns its reputation, and they are a large part of why a given tumor is triaged to Mohs rather than a standard excision, the decision explained in when Mohs is the right choice.
Biopsy margins are not the final word. Many reports state that the tumor extends to the edge of the biopsy specimen. That is expected: a biopsy samples the lesion to make the diagnosis, it does not try to remove it. A positive biopsy margin simply confirms that treatment is needed; it says little about the tumor's true footprint, which is exactly what the Mohs procedure maps in real time on surgery day.
Some phrases sound scarier than they are, and one deserves attention. Ulceration, solar elastosis, and inflammation are descriptive findings, common on sun-damaged skin and not alarming on their own. The phrase perineural invasion, meaning tumor tracking along a small nerve, does warrant a careful conversation, since it raises the stakes and sometimes changes the plan, but it is uncommon and it is exactly the situation where microscopic margin control matters most. The National Cancer Institute publishes a plain-language guide to reading pathology reports that is worth an evening (NCI: pathology reports), and MedlinePlus maintains a good primer on skin cancer generally (MedlinePlus: skin cancer).
Bring three questions to the consult. First, what is the subtype, and does it change the recommended treatment? Second, why is Mohs, or a standard excision, the right tool for this particular tumor and location? Third, what would the repair likely look like here? A surgeon who answers those three clearly, in plain language, is telling you they have actually read your pathology rather than pattern-matched your diagnosis.
The reassuring frame is that by the time a report is in your hands, the hardest step, finding the cancer while it is small, is already done. The report is not a verdict; it is a map, and for the common skin cancers it almost always points to a treatment with an excellent cure rate.
Related reading: Advances in skin cancer detection and Mohs.